Drug Profile
Co-crystallised fasoracetam - Avalo Therapeutics
Alternative Names: AEVI-004Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Aevi Genomic Medicine
- Developer Avalo Therapeutics
- Class Antiepileptic drugs; Neuroprotectants; Nootropics; Piperidines; Small molecules
- Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Metabotropic glutamate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder; Autistic disorder; Epilepsy
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Epilepsy in USA (PO)
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Attention-deficit-hyperactivity-disorder(In adolescents, In children) in USA (PO)
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Autistic-disorder in USA (PO)